Medizinische Universität Graz Austria/Österreich - Forschungsportal - Medical University of Graz
Gewählte Publikation:
SHR Neuro Krebs Kardio Lipid Stoffw Microb
Skrabl-Baumgartner, A; Seidel, G; Langner-Wegscheider, B; Schlagenhauf, A; Jahnel, J.
Drug monitoring in long-term treatment with adalimumab for juvenile idiopathic arthritis-associated uveitis.
Arch Dis Child. 2019; 104(3):246-250
Doi: 10.1136/archdischild-2018-315060
Web of Science
PubMed
FullText
FullText_MUG
- Führende Autor*innen der Med Uni Graz
- Skrabl-Baumgartner Andrea
- Co-Autor*innen der Med Uni Graz
- Jahnel Jörg
- Langner-Wegscheider Beate Julia
- Schlagenhauf Axel
- Seidel Gerald
- Altmetrics:
- Dimensions Citations:
- Plum Analytics:
- Scite (citation analytics):
- Abstract:
- Assessing influence of anti-adalimumab (ADA) antibodies (AAA) on serum trough ADA levels and uveitis activity in long-term ADA treatment of juvenile idiopathic arthritis (JIA)-associated uveitis. This prospective observational study included 20 patients from a single centre treated with ADA for active uveitis refractory to conventional disease-modifying antirheumatic drugs. AAA, serum ADA trough levels and uveitis activity were evaluated at regular intervals up to 6 years. AAA were detected in nine patients (45%). Permanent AAA in seven were associated with undetectable ADA trough levels and loss of response (LOR). Transient AAA were detected in four with measurable ADA trough levels and response of uveitis to treatment, followed in two by permanent AAA associated with LOR. Use of concomitant immunosuppression was significantly higher in patients without AAA (p<0.05). AAA-associated LOR frequently occurs in long-term treatment with ADA for JIA-associated uveitis. Concomitant immunosuppressive therapy significantly reduces the risk of LOR due to AAA. © Author(s) (or their employer(s)) 2019. No commercial re-use. See rights and permissions. Published by BMJ.
- Find related publications in this database (using NLM MeSH Indexing)
- Adalimumab - administration & dosage
- Adalimumab - adverse effects
- Adalimumab - immunology
- Anti-Inflammatory Agents - administration & dosage
- Anti-Inflammatory Agents - adverse effects
- Anti-Inflammatory Agents - immunology
- Antibodies - metabolism
- Antirheumatic Agents - administration & dosage
- Antirheumatic Agents - adverse effects
- Antirheumatic Agents - immunology
- Arthritis, Juvenile - drug therapy
- Arthritis, Juvenile - physiopathology
- Child -
- Drug Administration Schedule -
- Drug Monitoring -
- Female -
- Humans -
- Long-Term Care -
- Male -
- Prospective Studies -
- Treatment Outcome -
- Uveitis - drug therapy
- Uveitis - physiopathology
- Visual Acuity - physiology